Bitter melon (Momordica charantia) seed extracts (BMSE) have been used as traditional medicine for treating various ailments, although in many cases, the active component(s) are unidentified. In this study, bitter melon seeds were extracted in water, ethanol, or ethanol: water (1:1). The aqueous seed extracts (BMSE-W) exhibited marked cytotoxicity towards human embryonic kidney 293T (HEK293T) and human colon tumor 116 (HCT116) cells. The activity in BMSE-W was unaffected by heat and proteinases treatments, and eluted in the total volume of size-exclusion HPLC, suggesting the small, organic nature of the active component(s). Gas chromatographic-mass spectrometic (GC-MS) analysis of the HPLC fractions identified methoxy-phenyl oxime (MPO) as a major active component. Acetophenone oxime, a commercially available structural homolog of MPO, demonstrated cytotoxicity comparable with that of the BMSE-W. The oxime functional group was found to be critical for activity. Increased poly-(ADP-ribose)-polymerase and β-actin cleavage, and chromatin condensation observed in treated cells suggested apoptosis as a plausible cause for the cytotoxicity. This study, for the first time, identified a cytotoxic oxime in BMSE-W.
GroverJK, YadavSP. (2004) Pharmacological actions and potential uses of Momordica charantia: A review. Journal of Ethnopharmacology, 93, 123–132.
2.
KuttanG, PratheeshkumarP, ManuKA, KuttanR. (2011) Inhibition of tumor progression by naturally occurring terpenoids. Pharmaceutical Biology, 49, 995–1007.
3.
SemizA, SenA. (2007) Antioxidant and chemoprotective properties of Momordica charantia L. (bitter melon) fruit extract. African Journal of Biotechnology, 6, 273–277.
4.
ManabeM, TakenakaR, NakasaT, OkinakaO. (2003) Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Bioscience Biotechnology and Biochemistry, 67, 2512–2517.
5.
JiratchariyakulW, WiwatC, VongsakulM, SomanabandhuA, LeelamanitW, FujiiI, SuwannarojN, EbizukaY. (2001) HIV inhibitor from Thai bitter gourd. Planta Medica, 67, 350,353.
6.
RamanA, LauC. (1996) Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine, 2, 349–362.
7.
Trivedi RashmiV, Wadher KamleshJ, Taksande JayashriB, Umekar MilindJ. (2011) Bitter melon: A bitter body with a sweet soul. International Journal of Ayurveda Research and Pharmacy, 2, 443–447.
8.
KrawinkelMB, GudrunB. (2006) Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia. Nutritional Review, 64, 331–337.
9.
GadangV, GilbertW, HettiararchchyN, HoraxR, KatwaL, DevareddyL. (2011) Dietary bitter melon seed increases peroxisome proliferator-activated receptor-gamma gene expression in adipose tissue, down-regulates the nuclear factor-kappa b expression, and alleviates the symptoms associated with metabolic syndrome. Journal of Medical Food, 14, 86–93.
10.
JilkaC, StriflerB, FortnerGW, HaysEF, TakemotoDJ. (1983) In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Research, 43, 5151–5155.
11.
RayRB, RaychoudhuriA, SteeleR, NerurkarP. (2010) Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Research, 70, 1925–1931.
12.
XiongSD, YuK, LiuXH, YinLH, KirschenbaumA, YaoS, NarlaG, DiFeoA, WuJB, YuanY, HoSM, LamYW, LevineAC. (2009) Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. International Journal of Cancer, 125, 774–782.
13.
PuriM, KaurI, KanwarRK, GuptaRC, ChauhanA, KanwarJR. (2009) Ribosome inactivating proteins (rips) from Momordica charantia for anti viral therapy. Current Molecular Medicine, 9, 1080–1094.
14.
BarbieriL, ZamboniM, LorenzoniE, MontanaroL, SpertiS, StirpeF. (1980). Inhibition of protein synthesis in vitro by proteins from the seeds of Momordica charantia (bitter pear melon). The Biochemical Journal, 186, 443–52.
15.
IslamMR, HirayamaH, FunatsuG. (1991). Complete amino acid sequence of luffin-b, a ribosome-inactivating protein from the sponge gourd (Luffa cylindrica) seeds. Bioscience Biotechnology and Biochemistry, 55, 229–238.
16.
TsePMF, NgTB, FongWP, WongRNS, WanCC, MakNK, YeungHW. (1999) New ribosome-inactivating proteins from seeds and fruits of the bitter gourd Momordica charantia. The International Journal of Biochemistry & Cell Biology, 31, 895–901.
17.
ChanLY, WangCKL, MajorJM, GreenwoodKP, LewisRJ, CraikDJ, DalyNL. (2009) Isolation and characterization of peptides from Momordica cochinchinensis seeds. Journal of Natural Products, 72, 1453–1458.
18.
GrossmannME, MizunoNK, DammenML, SchusterT, RayA, ClearyMP. (2009) Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prevention Research (Philadelphia), 2, 879–86.
19.
KoboriM, Ohnishi-KameyamaM, AkimotoY, YukizakiC, YoshidaM. (2008) Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. Journal of Agriculture Food Chemistry, 56, 10515–10520.
20.
SiriamornpunS, KubolaJ. (2008) Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro. Food Chemistry, 110, 881–890.
CuiJG, FanL, HuangLL, LiuHL, ZhouAM. (2009) Synthesis and evaluation of some steroidal oximes as cytotoxic agents: Structure/activity studies (i). Steroids, 74, 62–72.
23.
KwonHJ, YoshidaM, NagaokaR, ObinataT, BeppuT, HorinouchiS. (1997) Suppression of morphological transformation by radicicol is accompanied by enhanced gelsolin expression. Oncogene, 15, 2625–31.
24.
SogaS, NeckersLM, SchulteTW, ShiotsuY, AkasakaK, NarumiH, AgatsumaT, IkuinaY, MurakataC, TamaokiT, AkinagaS. (1999) Kf25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of hsp90 binding signaling molecules. Cancer Research, 59, 2931–2938.
25.
WhitesellL, LindquistSL. (2005) Hsp90 and the chaperoning of cancer. Nature Reviews Cancer, 5, 761–772.
26.
RileySRR, VickeryRD, NemethGA, HaasMJ, KasprzakDJ, MaurinMB. (2011) Thermal decomposition of matrix metalloproteinase inhibitors: Evidence of solid state dimerization. Journal of Pharmacetical Biomedical Analysis, 54, 324–330.
27.
OverallCM, KleifeldO. (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. British Journal of Cancer, 94, 941–946.
28.
BoularesAH, YakovlevAG, IvanovaV, StoicaBA, WangG, IyerS, SmulsonM. (1999) Role of poly(adp-ribose) polymerase (parp) cleavage in apoptosis. Caspase 3-resistant parp mutant increases rates of apoptosis in transfected cells. Journal of Biochemical Chemistry, 274, 22932–40.
29.
HanahanD, WeinbergRA. (2000) The hallmarks of cancer. Cell, 100, 57–70.
30.
StauntonMJ, GaffneyEF. (1998) Apoptosis - basic concepts and potential significance in human cancer. Archives of Pathology & Laboratory Medicine, 122, 310–319.
31.
StrasserA, CoryS, AdamsJM. (2011) Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. Embo Journal, 30, 3667–3683.
